

Freedom of Information Request	FOI 21-200	9 th June 2021
--------------------------------	------------	---------------------------

1. For the 4-month period from January to April 2021, how many patients has your trust treated with the following anti-VEGF treatments:

- **Aflibercept**
- **Bevacizumab**
- **Brolucizumab**
- **Dexamethasone**
- **Fluocinolone acetonide**
- **Ranibizumab**

The Health Board is unable to supply this information as the pharmacy system does not differentiate between quantities issued for anti-VEGF treatment against its other indications. In order to determine this it would have to review every patient record. Therefore in order to comply with your request the Health Board has established that this would exceed the appropriate costs limit under Section 12 of the Freedom of Information Act 2000 which is currently £450. As you will be aware this is not an exemption which requires us to consider the application of the public interest test. We have calculated that it would take in excess of 18 hours to review the record of each patient.

2. For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy.

- **Aflibercept**
- **Bevacizumab**
- **Brolucizumab**
- **Dexamethasone**
- **Fluocinolone acetonide**
- **Ranibizumab**

Please see response as per Question 1.

3. Within your trust, how many intra-vitreous injections/implants of each the following treatments have been used (for any eye condition) in the four-month period from January to April 2021:

For the period January 2021 – April 2021 the following quantities were dispensed for Ophthalmology:

- **Aflibercept 3.6mg PF Syringe** = 3431
- **Bevacizumab PF Syringe** = 2
- **Brolucizumab** = 0
- **Dexamethasone 700microgram implant** = 1
- **Fluocinolone 190microgram implant** = 1
- **Ranibizumab 10mg/1ml PF Syringe** = 1161

4. Retinal Vein Occlusion - Central (CRVO) or Branch (BRVO)

- **Aflibercept**
- **Bevacizumab**
- **Dexamethasone**
- **Ranibizumab**

Please see response as per Question 1.

- 1. Who is the Chief Information/Technology Officer at the organisation? Please provide their name and job title**
Matthew Mahoney, Interim Chief Technical Officer
- 2. Does the organisation have a team/department that handles digital innovation?**
The Health Board does not have a dedicated team for this purpose
 - a. If yes, please name these teams/departments and the members names and job titles.**
- 3. Does the team/department develop front facing service user websites/apps?**
Yes
 - a. if yes, please state the websites/apps developed and their use.**
Clinical Workstation - local clinical portal for clinicians
- 4. Have the team/department ever applied for external tenders for healthcare developments?**
No
 - a. If yes, please state which external tenders.**
N/A
- 5. Have the teams/departments ever done developments for other organisations/external entities?**
No
 - a. If yes, please provide details on the developments**
N/A
- 6. Have the teams/departments ever sold a development it has produced commercially?**
No
 - a. If yes, please provide details of the development sold**
N/A
- 7. Have the teams/departments ever attempted to secure an innovation grant?**
Yes
 - a. If yes, please state which innovation grant and if they were successful**
Scale and Spread (Not successful) Welsh Government Efficiency through Tech fund